Table 2. Mycoplasma genitalium infections among 114 patients cured after 10 days of pristinamycin treatment, Melbourne Sexual Health Centre, Melbourne, Victoria, Australia, 2012–2016.
| Subgroup | Pristinamycin failure, no. (%) | Cured, no. (%, 95% CI) | p value* |
|---|---|---|---|
| Overall |
29 (25) |
85 (75, 66–82) |
|
| Dosage regimen | |||
| Pristinamycin 2 g/d | 2 (22) | 7 (78, 40–97) | 0.91 |
| Pristinamycin 3 g with doxycycline 200 mg/d | 14 (26) | 40 (74, 60–85) | |
| Pristinamycin 4 g/d |
13 (25) |
38 (75, 60–86) |
|
| Site of infection | |||
| Urethral infection, M | 22 (29) | 55 (71, 60–81) | 0.20 |
| Anorectal infection |
4 (14) |
24 (86, 67–96) |
|
| Patient sex | |||
| F | 3 (27) | 8 (73, 39–94) | 1.0 |
| M |
26 (25) |
77 (75, 65–83) |
|
| Patient signs/symptoms | |||
| Symptomatic | 28 (29) | 70 (71, 61–80) | 0.07 |
| Asymptomatic | 1 (6) | 15 (94, 70–100) |
*The 3 dosage regimens were compared by nonparametric test for trend. Fisher exact test used for other variables.